Commentary

Book Review: DuPont’s approach to addiction is tough, yet compassionate


 

Focus on prevention

A clear passion for prevention is evident within his chapters on youth addiction. For adolescents, Dr. DuPont presents a “One Choice approach,” which requires complete abstinence from alcohol, tobacco, and marijuana. He also presents science showing that patients younger than age 21 will have a greater risk of developing lifelong and debilitating addictions if they use these chemicals prior to this age. His emphasis for the One Choice approach carries ramifications throughout the primary care, pediatric, and family practice communities.

Dr. DuPont is nothing if not an optimist. Though he clearly defines addiction as an often-fatal disease, he remains positive about the future of addiction treatment, both with changes in public policy and with advancements in the medicine of addiction. He makes a compelling argument regarding Sweden’s approach to the drug problem, citing Queen Silvia’s lifelong commitment to prevent, control, and treat drug and alcohol addiction. Sweden’s model is, indeed, intriguing, and that country’s outcomes present a strong argument for the marriage of the criminal justice system with medical intervention – an approach that the United States has adopted only in a patchwork fashion.

Dr. Lantie Elisabeth Jorandby, an addiction psychiatrist with Amen Clinics in Washington Courtesy Dr. Jorandby

Dr. Lantie Elisabeth Jorandby

The book describes controversies throughout, such as Dr. DuPont’s furtherance of our work on how best to treat dual disorders.2 He is not impressed with the self-medication hypothesis as well as the dive into the U.S. national medical marijuana experiment. We had looked at college students having new-onset memory or attention-deficit/hyperactivity problems, only to find that it was likely psychostimulant seeking to reverse marijuana effects.3 Physicians, families, and patients would be well served to review his arguments on the clear definition of “medicine” with regard to marijuana and the risks taken when we medicalize a known addictive chemical. He tackles the push for legalization as well, and the risks of increased societal acceptance and commercialization power that comes with this. He has led the field in thinking about the role of early drug exposure, brain training, and hijacking in the addictive process. This gateway hypothesis can occur whether the first teen drugs are cannabis or tobacco4 or alcohol.

Dr. Mark S. Gold, 7th Distinguished Alumni Professor at the University of Florida, Gainesville, and professor of psychiatry (adjunct) at Washington University, St. Louis. He is chairman of the scientific advisory boards for RiverMend Health.

Dr. Mark S. Gold

Dr. DuPont finishes his work with a detailed biography, in which he addresses his family history of addiction, and his own overuse of alcohol in his late teens and early 20s as well as a confession of onetime use of marijuana during medical school. He always has led the field in trying to explain the disease of addiction, intervention, treatment, and recovery. But this self-reflection and brutal honesty is refreshing and in step with themes in his book, which promote the idea of recovery as an embrace of honesty, in mind, body, and spirit.

Dr. Jorandby trained in addiction psychiatry at Yale University, New Haven, Conn., and works as an addiction psychiatrist with Amen Clinics in Washington. Dr. Gold is the 17th Distinguished Alumni Professor at the University of Florida, Gainesville, and professor of psychiatry (adjunct) at Washington University in St. Louis.

References

1. J Subst Abuse Treat. 2009 Mar;36(2):159-71.

2. J Addict Dis. 2007;26 Suppl 1:13-23.

3. Am J Psychiatry. 2007 Jun;164(6):973.

4. J Addict Dis. 2003;22(3):51-62.

Pages

Recommended Reading

FDA issues new REMS for immediate-release opioids
MDedge Internal Medicine
Confirmed: Growth in overdose deaths is exponential
MDedge Internal Medicine
Cannabinoids may raise pain tolerance, not relieve pain itself
MDedge Internal Medicine
Signs point to growing abuse of gabapentinoids in the U.S.
MDedge Internal Medicine
Coagulopathy outbreak underscores danger of synthetic cannabinoids
MDedge Internal Medicine
House, Senate agree on broad opioid legislation
MDedge Internal Medicine
Does America have a gabapentinoid problem?
MDedge Internal Medicine
Teens who vape are likely to add cigarette smoking
MDedge Internal Medicine
Opiate use tied to hepatitis C risk in youth
MDedge Internal Medicine
Beyond the opioids
MDedge Internal Medicine